SCHEMBL7077219

SCHEMBL7077219

O=C(CC(=O)c1cnccn1)c1cccc(Cc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ PLOD2 O00469 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ KMT2A Q03164 4/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ HPGD P15428 3/20 0.44
▸ PLOD3 O60568 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ PLOD1 Q02809 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ PTPN1 P18031 1/20 0.43
▸ AGTR1 P30556 1/20 0.43
▸ PSMB11 A5LHX3 1/20 0.42
▸ PSMA7 O14818 1/20 0.42
▸ PSMB1 P20618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051212 0.84 ALDH1A1 (0.44) SMN1; SMN2PLOD2ALDH1A1KMT2ACYP1A2
SCHEMBL7077794 0.84 ALDH1A1 (0.44) SMN1; SMN2PLOD2ALDH1A1KMT2ACYP1A2
SCHEMBL7077243 0.81 PTPN1 (0.43) SMN1; SMN2PLOD2ALDH1A1KMT2ACYP1A2
SCHEMBL7077241 0.80 CTNNB1 (0.51) SMN1; SMN2PLOD2ALDH1A1KMT2ACYP1A2
SCHEMBL7079211 0.79 KDM4E (0.44) SMN1; SMN2PLOD2ALDH1A1KMT2ACYP1A2
SCHEMBL7077395 0.79 WNT3A (0.43) SMN1; SMN2PLOD2ALDH1A1
SCHEMBL7078439 0.78 NR3C2 (0.46) SMN1; SMN2ALDH1A1KMT2AMEN1HPGD
SCHEMBL7077399 0.78 SMN1; SMN2 (0.38) SMN1; SMN2PLOD2ALDH1A1PSMB11PSMA7
SCHEMBL7081681 0.78 CYP2E1 (0.48) PLOD2CYP2C9CYP2C19PLOD3CYP3A4
SCHEMBL7081081 0.77 MRGPRX4 (0.42) SMN1; SMN2ALDH1A1KDM4EPTPN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 — — US claimed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 — — EP claimed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 — — EP claimed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 — — WO claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 — — US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 — — EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 — — EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 SMN1; SMN2 4337/4885PLOD2 1597/4885ALDH1A1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback